Fingolimod in Endovascular Treatment of Ischemic Stroke
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor
modulator fingolimod may be efficacious in attenuating brain inflammation and improving
clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours
of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This
study aim to determine whether fingolimod enhance the action of endovascular treatment for
acute ischemic stroke